← All trials
NCT06980649
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 21, 2025
- Primary completion
- Mar 31, 2026
- Completion date
- Mar 31, 2026
- First posted
- May 20, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biohaven Pharmaceuticals Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.